Lyra Therapeutics, Inc. — Director's Dealing 2021

Sep 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyra Therapeutics, Inc. (LYRA)
CIK: 0001327273
Period of Report: 2021-09-13

Reporting Person: Cavalier Jason (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-13	Stock Options (Right to Buy)	$8.22	A	104000	Acquired	2031-09-12	Common Stock (104000)	Direct

Footnotes

F1: This option vests and becomes exercisable as to 25% of the underlying shares on September 13, 2022 and in 36 substantially equal monthly installments thereafter.